Biotherapeutics

The mission aims to support development of 2-3 biosimilars (therapeutic proteins and monoclonal antibodies)that are currently under development by the industry and bring them closer to the market in 5 years and simultaneously develop an ecosystem that would spur innovation to develop novel products.